Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • EGFR
    (29)
  • BTK
    (3)
  • Autophagy
    (2)
  • HER
    (2)
  • Apoptosis
    (1)
  • IRAK
    (1)
  • JAK
    (1)
  • Raf
    (1)
  • Tyrosine Kinases
    (1)
  • Others
    (14)
Filter
Search Result
Results for "

egfr (wt), egfr (t790m), egfr (l858r), egfr (l858r/t790m )

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    45
    TargetMol | Inhibitors_Agonists
Osimertinib
Mereletinib, AZD-9291
T24901421373-65-0
Osimertinib (AZD-9291) is an EGFR third-generation inhibitor that inhibits the T790M resistance mutation produced by second-generation EGFR inhibitors with irreversible and oral activity. Osimertinib has antitumor activity for the treatment of EGFR-mutated non-small-cell lung cancer.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
DBPR112
T109651226549-49-0In house
DBPR112 is an orally active furanopyrimidine-based EGFR inhibitor with IC50s of 15 nM for EGFRWT and 48 nM for EGFRL858R T790M, capable of occupying the ATP-binding site and demonstrating significant antitumor efficacy.
  • Inquiry Price
6-8 weeks
Size
QTY
EGFR-IN-9
T111631226549-39-8In house
EGFR-IN-9 is a potent EGFR kinase inhibitor with IC50s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R T790M). EGFR-IN-9 has antitumor activity.
  • Inquiry Price
6-8 weeks
Size
QTY
Afatinib Dimaleate
BIBW2992, BIBW 2992MA2, Afatinib (BIBW2992) Dimaleate, Afatinib
T1773850140-73-7
Afatinib Dimaleate (BIBW 2992MA2) is an orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity.
  • Inquiry Price
Size
QTY
Afatinib
BIBW 2992, Afatinib free base
T21312850140-72-6
Afatinib (BIBW 2992) is an irreversible inhibitor of the EGFR family (EGFR-wt, EGFR-L858R, EGFR-L858R T790M, and HER2) with IC50s of 0.5 nM, 0.4 nM, 10 nM, and 14 nM, respectively.
  • Inquiry Price
Size
QTY
(S)-Afatinib
BIBW2992
T2303439081-18-2
(S)-Afatinib (BIBW2992) is an irreversible EGFR family inhibitor with IC50s of 0.5 0.4 10 14 1 nM for EGFRwt, EGFR (L858R), EGFR (L858R T790M), HER2, and HER4, respectively.
  • Inquiry Price
Size
QTY
Avitinib
AC0010
T30241557267-42-1
Avitinib (AC0010), also known as AC0010 or AC0010MA, is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. Upon oral administration, avitinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the drug-resistant T790M EGFR mutant, which prevents signaling mediated by mutant forms of EGFR. This may both induce cell death and inhibit tumor growth in EGFR-mutated tumor cells. EGFR, a receptor tyrosine kinase that is mutated in a variety of Ys, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors, which also inhibit wild-type EGFR.
  • Inquiry Price
Size
QTY
EGFR mutant-IN-1
T11164
EGFR mutant- in-1, A 5-methylpyrimidopyridone derivative are effective selective EGFRL858R T790M C797S mutant inhibitors with IC50 of 27.5 nM, which significantly weakened EGFRWT effect.
  • Inquiry Price
8-10 weeks
Size
QTY
Rociletinib hydrobromide
AVL-301 hydrobromide, CO-1686 (hydrobromide), CNX-419 hydrobromide
T149931446700-26-0
Rociletinib hydrobromide is an orally delivered inhibitor of the mutant form of EGFR kinase (Kis: 21.5 nM and 303.3 nM for EGFR L858R T790M and EGFR WT).
  • Inquiry Price
7-10 days
Size
QTY
Mavelertinib
PF 06747775, PFE-X775, PF-06747775, PF-7775, PF 6747775, PF6747775
T213221776112-90-3
Mavelertinib (PF-06747775) is an orally available, selective and potent EGFR tyrosine kinase (EGFR TKI) inhibitor with inhibitory effects on T790M L858R and T790M Del, and can be used in the study of oncology and respiratory diseases.
  • Inquiry Price
7-10 days
Size
QTY
Lifirafenib
BGB-283, Beigene-283
T222721446090-79-4
Lifirafenib (Beigene-283) is a potent inhibitor of RAF family kinases and EGFR in biochemical assays with IC50 of 23, 29 and 495 nM for the recombinant BRAFV600E kinase domain, EGFR and EGFR T790M L858R mutant respectively.
  • Inquiry Price
6-8 weeks
Size
QTY
pf-6274484
PF 6274484
T223961035638-91-5
PF-6274484, a high affinity, irreversible covalent inhibitor of EGFR kinase with Ki of 0.14 nM, inhibits the autophosphorylation of wild-type EGFR in A549 cells and EGFRL858R T790M in H1975 cells with IC50 of 5.8 nM and 6.6 nM, respectively.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Rociletinib
AVL-301, CNX-419, CO-1686
T23691374640-70-6
Rociletinib (CNX-419) is an orally available small molecule, irreversible inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity.
  • Inquiry Price
Size
QTY
AZ-5104
T24911421373-98-9
AZ5104 is a potent EGFR inhibitor.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Nazartinib
EGF816, NVS-816
T35061508250-71-2
Nazartinib (EGF816) (EGF816, NVS-816) is a covalent, irreversible, mutant-selective EGFR inhibitor that has nanomolar inhibitory potency against activating mt (L858R, ex19del) and T790M mt, with up to 60-fold selectivity over wild type (wt) EGFR in vitro.
  • Inquiry Price
Size
QTY
Limertinib
ASK120067, ASK 120067
T358971934259-00-3
Limertinib (ASK120067) is an orally active and highly efficient epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor targeting EGFR T790M. Limertinib can be used for studying non-small cell lung cancer.
  • Inquiry Price
6-8 weeks
Size
QTY
avitinib maleate
T37211557268-88-8
Avitinib maleate is a pyrrolopyrimidine-based irreversible epidermal growth factor receptor (EGFR) inhibitor.
  • Inquiry Price
Size
QTY
Oritinib mesylate
SH-1028 mesylate,Oritinib mesylate
T396702180164-79-6
Oritinib mesylate (SH-1028) is a highly selective, orally active, pyrimidine-based irreversible inhibitor of epidermal growth factor receptor (EGFR) with a low IC50 of 18 nM. It is effective against both EGFR-sensitive and resistant (T790M) mutations and suppresses the proliferation of tumor cells harboring EGFR mutations, irrespective of their sensitivity or resistance.
  • Inquiry Price
1-2 weeks
Size
QTY
Lazertinib
Lazertinib (YH25448), GNS-1480, YH25448
T44851903008-80-9
Lazertinib (GNS-1480) is an effective, highly mutant-selective and irreversible EGFR-TKI with IC50 values of 1.7 nM, 2 nM, 5 nM, 20.6 nM and 76 nM for Del19 T790M, L858R T790M, Del19, L85R and Wild type EGFR respectively.
  • Inquiry Price
Size
QTY
oritinib
SH-1028
T600762035089-28-0
Oritinib (SH-1028) is an inhibitor of EGFR with IC50s of 18, 0.7, 4, 0.1, 1.4 and 0.89 nM for EGFR (wt), EGFR (L858R), EGFR (L861Q), EGFR (L858R T790M), EGFR (d746-750), EGFR (d746-750 T790M), respectively. Oritinib can be used in studies about the treatment of non-small cell lung cancer.
  • Inquiry Price
Size
QTY
egfr kinase inhibitor 1
T636482413958-04-8
EGFR kinase inhibitor 1 is a potent inhibitor of EGFR that acts on WT (IC50: 37 nM), l885R T790M (IC50: 1.7 nM), and L858R T790M C797S (IC50>300 nM). It is capable of blocking the cell cycle in G0 G1 phase, inducing apoptosis, and has an inhibitory effect on cell metastasis. Additionally, EGFR kinase inhibitor 1 exhibits anti-proliferative and anti-tumor effects.
  • Inquiry Price
8-10 weeks
Size
QTY
egfr-in-55
T636932057423-46-6
EGFR-IN-55 is a potent inhibitor of EGFR, acting on EGFRWT (IC50: 70 nM) and EGFRL858R T790M (IC50: 3.9 nM). EGFR-IN-55 was able to block the cell cycle of NCI-H1975 cells in G0 G1 phase, exhibiting anticancer effects.
  • Inquiry Price
6-8 weeks
Size
QTY
egfr-in-62
T63895
EGFR-IN-62 is a potent inhibitor of EGFR kinase with IC50 values of 10 nM for L858R T790 M, 29 nM for WT and 2 42 nM for L858R T790 M C797S. EGFR-IN-62 blocks the cell cycle of A549 and or H1975 cells in G1 G0 phase and induces apoptosis and motility inhibition. EGFR-IN-62 effectively inhibited the proliferation of A549 (IC50: 2.53 μM) and H1975 cells (IC50: 1.56 μM).
  • Inquiry Price
10-14 weeks
Size
QTY
afatinib oxalate
T640751398312-64-5
Afatinib (BIBW 2992) oxalate is an irreversible, orally active bispecific inhibitor of the ErbB family (EGFR and HER2) with IC50 values of 0.5 nM for EGFRwt, 0.4 nM for EGFRL858R, 10 nM for EGFRL858R T790M, and 14 nM for HER2. Afatinib oxalate can be used to study esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC), and gastric cancer.
  • Inquiry Price
1-2 weeks
Size
QTY